Moderna and Merck's cancer vaccine raises new treatment hope
Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.theglobeandmail.com — the content belongs to The Globe and Mail.
